Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Cingulate Inc (CING)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$4.24-7.02%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for CING yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Utilize $12M private placement proceeds effectively | A supporting condition in Cingulate Inc's published investment case. The stated target is Sustain operations using $12 million raised in private placements. | Improving | Capital runs out before end of FY26 without further funding | Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 12, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Review earningsObserved price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a speculative, loss-making biotech story rather than an established compounder. The thesis is still under watch: management is preparing to resubmit CTx-1301 after an FDA response, but confidence in the evidence snapshot is low.
The snapshot provides no valuation multiple or direct measure of market expectations, so whether CING is cheap or expensive versus peers cannot be assessed. The muted share-price reaction to recent developments suggests the news has not produced a strong market response, but it does not show what expectations are already priced in.
Near term, results may remain uneven: the company is loss-making, and its recent financial performance is neutral and below its industry cohort. Management is working on the FDA resubmission and commercial readiness, while cash rose to $28.4 million by 2026-Q2 and was described as extending runway into mid-2027; rising commercial spending and a possible earnings miss remain risks.
The multi-year thesis hinges on completing the CMC work, resubmitting the CTx-1301 application, and making progress toward launch readiness. Near term, weaker employment data could add pressure to cyclical healthcare names, while the sector backdrop could remain supportive if bellwether companies keep reporting strong results and guidance.
Over the next 1 to 3 years, CING remains a high-risk story whose thesis depends on regulatory progress, commercial execution, and enough financial runway. The evidence is limited and confidence is low. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Cingulate plans to resubmit the CTx-1301 NDA promptly after FDA feedback. |
| Improving |
| NDA resubmission delayed beyond next 4 quarters |
Qualitative: PK study published (Aug 2026) supports resubmission after CRL (Jun 2026) FDA CRL received June 2026; pharmacokinetic study published August 2026 supporting NDA resubmission. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “The Company is working closely with its manufacturing partner to complete this work and plans to resubmit the NDA to the FDA as promptly as practicable.” “This work follows a Complete Response Letter issued by the FDA on June 1, 2026, which identified specific requests for additional CMC information and did not identify any concerns regarding the clinical safety or efficacy of CTx-1301.” Delivery assessment Nov 4, 2026 |
Manage operating losses near -$7.9M Q1 2026 level | Operating losses are managed near -$7.9 million in Q1 2026. | Intact | Operating loss worsens beyond -$7.9 million per quarter | Operating income: $-5.415M FY2026-Q2; GAAP. Published target: Operating loss no worse than -$7.9 million per quarter. Target period is not explicitly aligned with this observation. Aug 13, 2026-5,414,975 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-1.20 → $-1.75 · observed estimates
$0.02B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-07-25 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-07-26 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-07-27 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-07-28 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-07-29 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-07-30 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-07-31 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-01 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-02 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-03 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-04 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-05 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-06 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-07 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-08 | $-0.74 | $20,035,800 | 4 / 5 |
| 2026-08-09 | $-0.74 | $20,035,800 | 4 / 5 |
| 2026-08-10 | $-0.74 | $20,035,800 | 4 / 5 |
| 2026-08-11 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-12 | $-0.74 | $20,035,800 | 4 / 5 |
| 2026-08-13 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-14 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-15 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-16 | $-1.20 | $17,007,667 | 4 / 4 |
| 2026-08-17 | $-1.20 | $17,007,667 | 4 / 4 |
| 2026-08-18 | $-1.20 | $17,007,667 | 4 / 4 |
| 2026-08-19 | $-1.20 | $17,007,667 | 4 / 5 |
| 2026-08-20 | $-1.13 | $17,007,667 | 4 / 5 |
| 2026-08-21 | $-1.27 | $19,924,167 | 4 / 5 |
| 2026-08-22 | $-1.27 | $19,924,167 | 4 / 5 |
| 2026-08-23 | $-1.27 | $19,924,167 | 4 / 5 |
| 2026-08-24 | $-1.27 | $19,924,167 | 4 / 5 |
| 2026-08-25 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-08-26 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-08-27 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-08-28 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-08-29 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-08-30 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-08-31 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-09-01 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-09-02 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-09-03 | $-1.23 | $19,924,167 | 4 / 5 |
| 2026-09-04 | $-1.83 | $8,929,000 | 4 / 5 |
| 2026-09-05 | $-1.83 | $8,929,000 | 4 / 5 |
| 2026-09-06 | $-1.83 | $8,929,000 | 4 / 5 |
| 2026-09-07 | $-1.83 | $8,929,000 | 4 / 5 |
| 2026-09-08 | $-1.83 | $8,929,000 | 4 / 5 |
| 2026-09-09 | $-1.83 | $8,929,000 | 4 / 5 |
| 2026-09-10 | $-1.83 | $8,929,000 | 4 / 5 |
| 2026-09-11 | $-1.83 | $8,929,000 | 4 / 5 |
| 2026-09-12 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-13 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-14 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-15 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-16 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-17 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-18 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-19 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-20 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-21 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-22 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-23 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-24 | $-1.75 | $12,168,000 | 4 / 5 |
| 2026-09-25 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-09-26 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-09-27 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-09-28 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-09-29 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-09-30 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-01 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-02 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-03 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-04 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-05 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-06 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-07 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-08 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-09 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-10 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-11 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-12 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-13 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-14 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-15 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-16 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-17 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-18 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-19 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-20 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-21 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-22 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-23 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-24 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-25 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-26 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-27 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-28 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-29 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-30 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-10-31 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-11-01 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-11-02 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-11-03 | $-1.75 | $12,168,000 | 4 / 4 |
| 2026-11-04 | $-1.75 | $12,168,000 | 4 / 4 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 4 Buy / Strong Buy · 0 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.